L-环丙基丙氨酸 | 102735-53-5

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-环丙基丙氨酸
• 中文别名: L-3-环丙基丙氨酸；3-环丙基-L-丙氨酸；L-3-(环丙基)丙氨酸
• 英文名称: (S)-2-amino-3-cyclopropylpropanoic acid
• 英文别名: (2S)-2-amino-3-cyclopropylpropanoic acid；L-cyclopropylalanine
• CAS: 102735-53-5
• 化学式: C₆H₁₁NO₂
• mdl: MFCD00798687
• 分子量: 129.159
• InChiKey: XGUXJMWPVJQIHI-YFKPBYRVSA-N

物化性质

• 沸点：
  258.0±23.0 °C(Predicted)
• 密度：
  1.218±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn,Xi
• 危险类别码：
  R22,R20/21/22,R36/37/38
• 海关编码：
  2922499990
• 安全说明：
  S26,S36,S36/37/39
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  -15°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: L-Cyclopropylalanine
Synonyms: (S)-2-Amino-3-cyclopropyl-propionic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: L-Cyclopropylalanine
CAS number: 102735-53-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H11NO2
Molecular weight: 129.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

L-环丙基丙氨酸是一种手性氨基酸衍生物，对非天然氨基酸的持续关注是因为它们广泛用作各种药物活性材料的关键组成部分。

制备

L-环丙基丙氨酸可以通过六步反应由环丙基甲醛和N-苯甲酰甘氨酸为原料制备得到。

反应信息

• 作为反应物：
  描述：

  L-环丙基丙氨酸 在 硫酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 tert-butyl (S)-3-N-formyl-3-cyclopropylalaninate
  参考文献：
  名称：

  三氟甲基取代的乙内酰脲，用于合理药物设计的多功能构建基块

  摘要：

  描述了从六氟丙酮和三氟丙酮酸的Boc保护的亚胺开始的制备简单的一锅合成的三氟甲基取代的乙内酰脲。它们代表了构建受约束的肽或作为合成高效VLA-4拮抗剂的支架的有价值的组成部分。

  DOI：

  10.1016/j.tet.2004.03.025
• 作为产物：
  描述：

  2-乙酰基氨基-3-环丙基丙酸 在 sodium hydroxide 、 porcine pancreatic acylase I 作用下， 以 水 为溶剂， 反应 4.0h， 以92%的产率得到L-环丙基丙氨酸
  参考文献：
  名称：

  A Convenient Synthesis Of (L)-β-Cyclopropylalanine

  摘要：

  A convenient, low cost, large scale synthesis of (L)-beta-cyclopropylalanine is reported.

  DOI：

  10.1080/00397919608003718

文献信息

• Synthesis and Structure−Activity Relationships of 2-Substituted <scp>d</scp>-Tryptophan-Containing Peptidic Endothelin Receptor Antagonists:  Importance of the C-2 Substituent of the <scp>d</scp>-Tryptophan Residue for Endothelin A and B Receptor Subtype Selectivity
  作者：Takehiro Fukami、Takeru Yamakawa、Kenji Niiyama、Hisaki Kojima、Yuuka Amano、Fuyuko Kanda、Satoshi Ozaki、Takahiro Fukuroda、Masaki Ihara、Mitsuo Yano、Kiyofumi Ishikawa

  DOI：10.1021/jm9600914

  日期：1996.1.1

  Continuing studies on modifications of potent cyclic pentapeptide endothelin (ET) receptor antagonists, represented by BQ-123, and potent linear tripeptide derivative ET receptor antagonists, represented by BQ-788, are described herein. The introduction of D-tryptophan analogues with C-2 substituents in these peptidic ET antagonists resulted in potent ET receptor antagonists with various ETA/ETB subtype selectivity

  本文描述了以BQ-123为代表的有效环状五肽内皮素（ET）受体拮抗剂和以BQ-788为代表的有效线性三肽衍生物ET受体拮抗剂的修饰的持续研究。在这些肽类ET拮抗剂中引入具有C-2取代基的D-色氨酸类似物，可产生具有各种ETA / ETB亚型选择性的有效ET受体拮抗剂。在环状五肽和线性三肽系列中都发现带有2-卤代和2-甲基-D-色氨酸的联合ETA / ETB受体拮抗剂。相反，具有2-氰基-D-色氨酸的化合物是ETB受体选择性拮抗剂。D-色氨酸残基的C-2取代基似乎对于区分拮抗剂的ETA / ETB亚型选择性非常重要。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2018006063A1

  公开（公告）日：2018-01-04

  Compositions and methods for the treatment of bacterial infections include compounds containing dimers of cyclic heptapeptides conjugated to one or more monosaccharide or oligosaccharide moieties. In particular, compounds can be used in the treatment of bacterial infections caused by Gram-negative bacteria.

  用于治疗细菌感染的组合物和方法包括含有环七肽二聚体与一个或多个单糖或寡糖基团结合的化合物。特别是，这些化合物可用于治疗由革兰氏阴性细菌引起的细菌感染。
• Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
  申请人：Madar J. David

  公开号：US20050215784A1

  公开（公告）日：2005-09-29

  The present invention relates to compounds that inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.

  本发明涉及抑制二肽基肽酶IV（DPP-IV）的化合物，用于预防或治疗糖尿病，特别是II型糖尿病，以及高血糖、X综合征、高胰岛素血症、肥胖、动脉粥样硬化和各种免疫调节性疾病。
• Pyrrolidine modulators of chemokine receptor activity
  申请人：Merck & Co., Inc.

  公开号：US06265434B1

  公开（公告）日：2001-07-24

  The present invention is directed to pyrrolidine compounds of the formula 1: (wherein R1, R2, R3, R4, R5, R6 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.

  本发明涉及式1的吡咯烷化合物：（其中R1、R2、R3、R4、R5、R6和n在此处定义），这些化合物可用作趋化因子受体活性的调节剂。具体来说，这些化合物可用作趋化因子受体CCR-5和/或CCR-3的调节剂。
• FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
  申请人：FORUM Pharmaceuticals Inc.

  公开号：US20170044182A1

  公开（公告）日：2017-02-16

  The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

  本公开涉及融合吗啉吡嘧啶类化合物，包括有效量的融合吗啉吡嘧啶类化合物的药物组合物，以及在治疗神经退行性疾病中使用融合吗啉吡嘧啶类化合物的方法，包括向需要的受试者施用有效量的融合吗啉吡嘧啶类化合物。